Objectives: To determine if low doses of topical latrunculin B (LAT-B) will increase outflow facility and decrease intraocular pressure without damaging the cornea and if they will inhibit miotic and accommodative responses to pilocarpine in monkeys.
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ATRUNCULINS, MACROLIDES
isolated from the marine sponge Latrunculia magnifica, are specific and potent actin-disrupting agents that sequester monomeric G-actin, leading to the disassembly of actin filaments. [1] [2] [3] Latrunculins A and B (LAT-A and LAT-B) are the 2 most common latrunculins, which cause reversible dose-dependent and timedependent destruction of actin bundles and associated proteins in varieties of cultured cells including human trabecular meshwork (TM) cells. [1] [2] [3] [4] [5] [6] [7] In living monkeys, both LAT-A and LAT-B increase outflow facility and decrease intraocular pressure (IOP). 6, 8, 9 Latrunculin-B also increases outflow facility in the organ-cultured anterior segment of porcine eyes, 5 suggesting a direct effect on outflow resistance in the conventional drainage pathway. The latter has been confirmed by a recent morphological study of the TM cells in the live monkey eye. 10 Because LAT-B, compared with LAT-A, is more potent in increasing outflow facility 6, 8 and produces fewer transient increases in aqueous humor formation, corneal endothelial permeability, and protein concentration in the anterior chamber (AC), 9 LAT-B may be a better candidate than LAT-A as a potential antiglaucoma medication. However, a single dose of 20 L of 500-M (approximately 0.02%) LAT-B administered topically, which decreases IOP in living monkeys, concentration of LAT-B might induce more apparent adverse effects in the cornea.
We hypothesized that repetitive lower concentrations and total doses in higher solution volumes, spread out over the entire corneal or conjunctival surface in the larger human eye, might minimize or avoid toxic effects on the cornea induced by high concentrations of cytoskeletal drugs without attenuating their effects on outflow resistance. 9, 11 To test this hypothesis, we determined the effects of a single or multiple doses of 0.005% or 0.01% topical LAT-B on outflow facility, IOP, and/or central corneal thickness (CCT) in normotensive monkey eyes. To learn more about the drug-induced changes in the anterior segment physiologic features, the pupil diameter and accommodation following 0.005% and 0.02% topical LAT-B administration were also determined.
METHODS
ANIMALS AND ANESTHESIA
Twenty-seven adult normal cynomolgus monkeys (Macaca fascicularis) of both sexes, weighing 3 to 8 kg, were studied; 8 for the tonometry and perfusion protocols, 5 for the pachymetry protocol, and 14 for the pupil and accommodation protocols (8 in the 0.02% LAT-B group and 6 in the 0.005% LAT-B group). All monkeys contributed 1 eye treated with the drug and 1 contralateral eye treated with vehicle. All experiments were conducted in accordance with University of Wisconsin-Madison and National Institutes of Health, Bethesda, Md, guidelines and with the Association for Research in Vision and Ophthalmology Statement on the Use of Animals in Ophthalmic and Vision Research. All monkeys were free of AC cells and flare by slitlamp biomicroscopy when studied. Anesthesia for tonometry or pachymetry was induced with intramuscular ketamine hydrochloride (10 mg/kg) and maintained with supplemental intramuscular injections as required (usually 5 mg/kg every 30 to 45 minutes). Anesthesia for AC perfusion or refractometry was induced with intramuscular ketamine hydrochloride (10 mg/kg) followed by intravenous pentobarbital sodium (15 mg/kg).
DRUG PREPARATION AND ADMINISTRATION
Latrunculin-B was obtained from Sigma Chemical Co (St Louis, Mo) and stored as a 2mM stock solution in dimethyl sulfoxide (DMSO) (Sigma Chemical Co) at −20ЊC. Latrunculin-B solutions for topical administration were freshly prepared in the Bárány solution 12 with 25% DMSO. Twenty microliters of 0.005% (1 g/20 L), 0.01% (2 g/20 L), or 0.02% (4 g/20 L) LAT-B were composed of 1.26, 2.53, or 5.00 L of 2mM LAT-B stock solution in DMSO and 15 L of the Bárány solution, with an additional 3.74 or 2.47 L of DMSO added into the 0.005% or 0.01% drug solution, so that each drug solution had 25% DMSO. Twenty-five percent DMSO served as a vehicle control. In IOP protocols, the drug or vehicle solution was administered to the central cornea of opposite eyes of either ketamineanesthetized (day 1 and day 5; 4ϫ5-L drops at each treatment) or fully conscious and manually restrained monkeys (day 2 through day 4; 2ϫ10-L drops at each treatment) twice daily for 4.5 days at 8 AM and 4 PM. Eyedrops were administered at 30-to 60-second intervals with blinking prevented between drops. Following the 0.01% LAT-B IOP experiment, the monkeys were treated with 0.01% drug and vehicle solution at 4 PM on day 5 and then once (days 6 and 7) or twice (day 8) daily (2ϫ10 L at each treatment) for 3 additional days while fully conscious and manually restrained. On day 9, these monkeys were treated again with the same dose of the drug (4ϫ5 L at each treatment) after receiving ketamine anesthesia 2 hours before the AC perfusion. For pachymetry, different monkeys were treated with 0.01% LAT-B twice daily for 4.5 days after receiving ketamine anesthesia. For refractometry and pupildiameter measurement, monkeys were treated with 0.005% and 0.02% LAT-B (4ϫ5 L at each treatment) 1 time after receiving ketamine and pentobarbital anesthesia. Administering the drug and vehicle solution to fully conscious and manually restrained monkeys in the IOP and outflow facility protocol was designed to reduce any potential cumulative effect of repeated ketamine administration on IOP or outflow facility during the multiple treatments.
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IOP MEASUREMENT
Intraocular pressure was determined on day 1 (before and after the first dose) and on day 5 (before and after the ninth dose) with a minified Goldmann applanation tonometer, 14 using halfand-half creamer solution (Borden Inc, Columbus, Ohio) as the tear film indicator, with the monkey lying prone in a head holder. For each eye, 3 IOP readings were averaged as a baseline or pretreatment IOP before administration of the first or ninth dose of 0.005% or 0.01% LAT-B or vehicle, and single IOP readings were taken after the drug and vehicle administration hourly for 6 hours. The 2-dose IOP protocols were conducted within a successive period of 2 weeks to observe the cumulative doseresponse relationship during a short period. The same eyes of the same animals were treated with the drug in the 2 IOP protocols, with the 0.01% LAT-B experiment performed the week immediately following the 0.005% LAT-B experiment. Since there was only a 2-day washout period, some ocular hypotensive effect of the 0.005% dose may have been carried over to the 0.01% dose protocol, but this cumulative dose-response strategy, which is often used in pharmacological studies, does not affect our overall conclusions.
OUTFLOW FACILITY MEASUREMENT
Total outflow facility was determined by 2-level constant pressure perfusion of the AC with the Bárány mock aqueous humor, 12 using a 1-needle technique and correcting for internal apparatus resistance. 15 Outflow facility was measured for 90 minutes 2 hours after the fifteenth dose of 0.01% LAT-B or vehicle on day 9.
CCT MEASUREMENT
Central corneal thickness was determined by ultrasonic pachymetry (DGH-1000 ultrasonic pachymeter; DGH Technology, Inc, Solana Beach, Calif) on day 1 (before and after the first dose) and day 5 (before and after the ninth dose). For each eye, 3 readings were averaged as a baseline or pretreatment value before administration of the first or ninth dose of 0.01% LAT-B or vehicle, and single readings were taken after the drug and vehicle administration every 30 minutes for 4 hours and then hourly for 2 hours.
PUPIL AND ACCOMMODATION MEASUREMENT
Accommodation (difference between baseline and postdrug refraction) was determined with a Hartinger coincidence refractometer (Zeiss-Jena, Jena, Germany). Pupil diameter was measured with Vernier calipers under normal room light (350 lux). Baseline refraction and/or pupillary diameter were measured, followed by topical application of 2.5% phenylephrine (stimu- lates the iris dilator muscle without influencing the iris sphincter and ciliary muscle, 16, 17 facilitating measurement of miosis and accommodation 18 ). Refraction and/or pupillary diameter were measured again approximately 30 minutes later, after which 20 L (4ϫ5 L for each treatment) of 0.005% or 0.02% LAT-B were administered topically to one eye and vehicle to the other. Refraction and pupillary diameter were determined 85 minutes after LAT-B administration. Five minutes later, approximately 3 mL of pilocarpine solution were infused intramuscularly in the thigh (1.5 mg/kg) across 10 minutes. Refraction was determined every 5 minutes after pilocarpine infusion until stable, and final pupillary diameter was then measured. The intramuscular infusion of pilocarpine as described earlier allowed us to measure dose-dependent accommodation during the drug administration, where, in effect, time becomes the dose. This method allowed us to look for differences in the absolute amplitude of the accommodative response and for any leftward or, more likely, rightward shift in the "dose-response" curve of the eye treated with LAT-B relative to the contralateral control eye. 19, 20 Furthermore, systemic administration assures that both eyes receive the same pilocarpine dose at all times, making the comparison between the eyes at each point still more valid and precise.
SLITLAMP EXAMINATION
Slitlamp biomicroscopy was performed before drug administration, during IOP measurement (1, 3, and 6 hours after drug administration), and before pachymetry and AC perfusion. The integrity of the corneal epithelium and endothelium, the presence of flare or cells in the AC, and the clarity of the lens, were noted. All animals were free of preexisting ocular abnormalities when studied.
DATA ANALYSIS
Data are given as meanϮSEM for number of eyes or animals. Predrug or postdrug treated vs contralateral control; postdrug or postvehicle vs ipsilateral baseline; and baseline-corrected postdrug treated vs control comparisons were made using the 2-tailed paired t test for differences vs 0.0 or ratios vs 1.0. The baseline IOP used for the data analysis in the 0.005% LAT-B or 0.01% LAT-B protocol was the IOP measured immediately before the first treatment of the corresponding dose of the drug or vehicle.
RESULTS
INTRAOCULAR PRESSURE
A single dose of 0.005% LAT-B lowered IOP from mean Ϯ SEM 19.3 Ϯ 0.8 to 16.4 Ϯ 0.7 mm Hg within 6 hours. After adjustment for baseline and contralateral IOP, 21 the maximal meanϮSEM hypotension of 2.5Ϯ0.3 mm Hg (n=8; PϽ.001) occurred at hour 6. Multiple doses (9 doses) of 0.005% LAT-B reduced IOP similar to a single dose but the significant IOP reduction occurred earlier (hour 1 vs hour 3) and the maximal ocular hypotension was slightly greater (mean Ϯ SEM, 3.2 Ϯ 0.5 mm Hg; PϽ.001). Intraocular pressure at 16 hours after the eighth treatment (IOP at 0 hours on day 5) in the eye treated with LAT-B was significantly lower than that in the contralateral control eye (meanϮSEM, −1.4Ϯ 0.3 mm Hg; PϽ.005) ( Figure 1A) . A single dose of 0.01% LAT-B lowered IOP from meanϮ SEM 18.8Ϯ 0.7 to 15.7Ϯ0.8 mm Hg within 6 hours. After adjustment for baseline and contralateral IOP, the maximal meanϮSEM hypotension of 2.7Ϯ0.6 mm Hg (n=8; PϽ.005) occurred at hour 3. Multiple doses (9 doses) of 0.01% LAT-B induced a greater IOP reduction than a single dose, with the maximal meanϮ SEM hypotension of 4.4Ϯ0.6 mm Hg (PϽ.001) at hour 4. The IOP measured before the ninth treatment (IOP at 0 hours on day 5) in the eye treated with LAT-B tended to be lower than that in the contralateral control eye (mean Ϯ SEM, −1.7 Ϯ 0.7 mm Hg; P = .056). Although the monkeys had not received any treatment for 3 days after the ninth treatment with 0.005% LAT-B, the baseline IOP (IOP at 0 hours on day 1) in the eye treated with LAT-B in the 0.01% LAT-B protocol ( Figure 1B ) did not return to the level before the first treatment with 0.005% LAT-B ( Figure 1A ).
OUTFLOW FACILITY
Latrunculin B significantly increased outflow facility by meanϮSEM 75%Ϯ13% (n=7; PϽ.005) during the overall 90-minute postdrug perfusion beginning 2 hours after the 15th treatment of 0.01% LAT-B. The total number of monkeys was 7 rather than 8 because 1 monkey died on day 6 of a disease unrelated to the experiment. In analysis of three 30-minute perfusion periods, the drug increased outflow facility by mean Ϯ SEM 35% Ϯ 14%, 69%Ϯ14%, and 100%Ϯ14% in the first, second, and third 30-minute durations, respectively ( and vehicle to the opposite eyes of monkeys topically twice daily for 4.5 days. Intraocular pressure (IOP) was measured before and after the first (on day 1) and ninth (on day 5) treatment. The same eyes of the same monkeys were treated with the drug in the 2-dose studies, and the higher-dose experiment was conducted the week immediately following the lower-dose experiment, with only 2 days' drug-free interval between studies. The IOP before the first treatment in each study was used as a baseline. shows that the increase in outflow facility was both time dependent and pressure dependent. There was no facility increase initially when the perfusion was started at the spontaneous IOP of the monkey eye 2 hours following administration of LAT-B or vehicle (spontaneous IOP of pentobarbital-anesthetized normal monkeys is typically Ͻ10 mm Hg 22 ), but a progressive increase occurred across time during perfusion at an elevated IOP (15 or 25 mm Hg) even though the drug concentration in the AC must have been decreasing because of the infusion of drug-free fluid and secretion of drug-free aqueous humor into the eye.
CENTRAL CORNEAL THICKNESS
On day 1, meanϮ SEM baseline CCT was 456.3Ϯ 17.0 m in the eye treated with LAT-B and 457.7Ϯ18.2 m in the contralateral control eye. MeanϮSEM CCT after the first treatment varied between 454.6 Ϯ 17.2 and 462.4Ϯ17.0 m in the eye treated with LAT-B and between 453.4Ϯ15.4 and 458.6Ϯ18.7 m in the contralateral control eye during 6-hour pachymetry. On day 5, the meanϮSEM CCT measured before the ninth treatment was 448.4Ϯ17.9 m in the eye treated with LAT-B and 455.9Ϯ18.6 m in the contralateral control eye. The mean Ϯ SEM CCT after the ninth treatment varied between 454.4Ϯ16.4 and 462.2Ϯ18.2 m in the eye treated with LAT-B and between 452.2Ϯ 18.8 and 457.2Ϯ 19.6 m in the contralateral control eye during 6-hour pachymetry. Collectively, the meanϮSEM CCT in the eye treated with LAT-B was only 0.9 to 8.1 m (P = .08-.82) or 3.1 to 7.1 m (P=.07-.37) thicker than that in the eye treated with vehicle after 1 or 9 doses of 0.01% LAT-B, after adjustment for ipsilateral baseline (Figure 3) .
PUPIL AND ACCOMMODATION MEASUREMENT Pupillary Diameter
Baseline pupil diameters of both eyes in all monkeys were similar ( Figure 4A and C) . Twenty-five minutes after phenylephrine administration, both pupils dilated equally (in the 0.02% LAT-B protocol, meanϮSEM, 7.2Ϯ0.3 mm vs 7.2Ϯ0.3 mm; n=8; PϽ.20) (Figure 4A ) (in the 0.005% LAT-B protocol, meanϮSEM, 7.0Ϯ0.3 mm vs 7.0Ϯ0.3 mm; n=6; PϽ.40) ( Figure 4C ). Eighty-five minutes after topical administration of 20 L of 0.02% LAT-B, the pupils in the eyes treated with LAT-B dilated further relative to the contralateral controls (to meanϮSEM 8.0Ϯ0.3 mm vs 7.0Ϯ0.4 mm; PϽ.005) ( Figure 4A ). However, 85 minutes after 20 L of 0.005% LAT-B, the pupils in the eyes treated with LAT-B were only slightly larger than those in the eyes treated with vehicle. When pilocarpine was infused intramuscularly in the thigh, the control pupils constricted but the pupils treated with 0.02% Figure 1B) , treatment with 0.01% LAT-B or vehicle to opposite eyes of monkeys topically once or twice daily was continued without interruption for 3 additional days. Outflow facility was measured by 2-level constant pressure perfusion for 90 minutes on day 9 (2 hours after the 15th treatment). No baseline outflow facility was determined, but all monkeys were selected from those that had similar baseline facilities in both eyes per previous studies. Data are expressed as mean ± SEM for 7 animals (n=7 rather than 8 because 1 monkey died in its cage of a disease unrelated to the experiment before perfusion). The difference between eyes was tested for differences vs 0.0 or by the 2-tailed paired t test. Figure 3. We administered 0.01% latrunculin B (LAT-B) and vehicle to the opposite eyes of monkeys topically twice daily for 4.5 days. Central corneal thickness (CCT) was measured before and after the first (on day 1) and ninth (on day 5) treatment. The CCT before the first treatment was used as a baseline. Data are expressed as mean ± SEM for 5 animals. The CCT difference between eyes corrected for baseline was tested for differences vs 0.0 or by the 2-tailed paired t test. * indicates PϽ.05. 
Effect of Latrunculin B (LAT-B) on Outflow Facility in
Accommodation
No significant differences between pilocarpine-induced accommodation in eyes treated with LAT-B vs control eyes were observed initially after 20 L of 0.02% LAT-B ( Figure 4B) . However, the accommodation plateau in the eyes treated with LAT-B occurred earlier than that in the control eyes (30 vs 40 minutes after the intramuscular pilocarpine). A statistically significant difference between eyes was observed during the period of 30 to 40 minutes after intramuscular pilocarpine, with the eyes treated with LAT-B accommodating approximately mean Ϯ SEM 2.5 Ϯ 0.5 diopters (D) (approximately 25%Ϯ8%) less than the controls (8.9 vs 11.4 D; n=5; PϽ.01) ( Figure 4B ). The accommodation was only slightly inhibited by 0.005% LAT-B ( Figure 4D ). The accommodative amplitude appears greater in the eyes treated with vehicle in the 0.005% LAT-B group compared with the eyes treated with vehicle in the 0.02% LAT-B group, which may be owing to the different durations of the measurement in the 2 groups. Other factors might also be involved, such as animal age (not available for some monkeys in the 0.02% LAT-B group), different accommodative amplitudes in different animals, differences in lag time for systemic bioavailability or distribution of the drug, and/or body weight of the animals, that might affect muscle mass and therefore distribution of the drug. In any case, the difference was not statistically significant by the 2-tailed unpaired t test (meanϮ SEM, 11.4Ϯ1.7 D vs 16.5Ϯ 2.2 D; PϾ.60), and the "different" accommodative amplitudes did not affect the major conclusions from the data obtained from comparison between contralateral eyes of the same monkey.
SLITLAMP EXAMINATION
During IOP measurement, most monkeys had mild punctate corneal epithelial defects at 3 to 6 hours after the drug administration, but the defects in eyes treated with LAT-B were similar to those in control eyes. Additionally, the punctate corneal epithelial defects seen during tonometry after the first treatment on day 1 had disappeared in both eyes of almost all monkeys at approximately 16 hours after the eighth dose (before tomometry on day 5). No other abnormality was observed in any monkey in any protocol during slitlamp examination. The heavily pigmented monkey conjunctivas precluded the evaluation of conjunctival hyperemia.
COMMENT
This study has shown that LAT-B administered topically decreases IOP in normotensive monkeys in a dosedependent manner, with multiple doses producing greater IOP reduction than a single dose. This is consistent with many current clinical and experimental antiglaucoma drugs that have greater effects following multiple treatments in both normotensive 21, 23 and glaucomatous 24, 25 monkeys. Some ocular hypotensive effect of multiple administrations of LAT-B appears to last more than 16 hours, evidenced by the lower IOP in the eyes treated with LAT-B than in the eyes treated with vehicle at 16 hours after the eighth treatment in both the 0.005% and 0.01% LAT-B protocols ( Figure 1A and B) and by the tendency toward slightly lower baseline IOP in the eyes treated with a drug than in the control eyes 3 days after the ninth treatment of 0.005% LAT-B ( Figure 1B) . The latter indicates that the cumulative effect of 0.005% LAT-B may affect the apparent IOP response to 0.01% LAT-B given subsequently. However, the IOP measured on day 5 in the 0.01% LAT-B protocol tended to increase 4 hours after the ninth treatment, which did not occur in the 0.005% LAT-B protocol. This seems to imply that it is more difficult for the drug to maintain a larger IOP reduction than a smaller one, although a higher dose is used. A more rapid rate of decrease in AC drug concentration due to greater resistance washout and greater reduction of the pressure gradient between the AC and the Schlemm canal following the higher dose than the lower dose may account for this phenomenon. Additionally, the same monkeys may have different IOPs or different responses to the drug on different occasions for a variety of rea- sons, including anesthetic considerations. Nevertheless, the IOP at 6 hours after the higher dose was still lower than that at 6 hours after the lower dose, which is consistent with the statement made earlier. In a previous study, 9 a single dose of 20 L of 500-M (approximately 0.02%) LAT-B maximally decreased IOP by 3.1 mm Hg, which is slightly greater than the maximal IOP reduction (−2.7 mm Hg) induced by a single dose of 0.01% LAT-B and apparently smaller than the IOP reduction (−4.4 mm Hg) induced by multiple doses of 0.01% LAT-B, in the current experiments. This further indicates that LAT-B dose dependently decreases IOP and that multiple doses of LAT-B are more effective than a single dose. In the present study, 15 treatments with 0.01% LAT-B time dependently and pressure dependently increased outflow facility in the monkey eye, which, in conjunction with our previous findings, 5, 8 suggests that LAT-B decreases IOP by reducing outflow resistance in the TM.
In the previous study, 9 a single dose of 0.02% topical LAT-B also transiently increased the CCT of the monkey eye by up to 47 m within 3 hours. Unlike the higher dose studied previously, a single and multiple doses of 0.01% LAT-B administered topically in the present study do not change the CCT. This indicates that the 0.01% concentration of the drug does not significantly affect the corneal endothelium. By slitlamp biomicroscopy, 0.01% LAT-B is also less toxic to the corneal epithelium than the higher dose studied before. 9 The LAT-B doses used in this study did not produce any additional punctate corneal epithelial defects in the eyes treated with LAT-B compared with the eyes treated with vehicle. The mild punctate corneal epithelial defects in both eyes, occurring 3 to 6 hours after the drug administration, are a common phenomenon during tonometry in ketamineanesthetized animals, presumably owing to reduced blinking under ketamine anesthesia and frequent IOP measurements. All these seem to support our hypothesis from previous studies 9, 11 that repetitive lower concentrations and total doses in higher solution volumes, spread out over the entire corneal or conjunctival surface, may minimize or avoid toxic effects on the cornea.
A recent morphological study 10 revealed that LAT-B induces formation of numerous cytoplasmic projections of the subcanalicular cells and massive "ballooning" of the juxtacanalicular region, leading to a substantial expansion of the space between the subcanalicular cell layer and the trabecular collagen beams. Additionally, LAT-B also significantly increases the junction-to-junction distance of the inner wall cells of the Schlemm canal, 10 although the increase is not as greatasthataftertheserine-threoninekinaseinhibitorH-7. 26, 27 All these structural changes in the TM may be consequent to the drug-induced cellular relaxation and account for the drug-induced decrease of outflow resistance in the TM. The current physiologic data indicate that LAT-B dosedependently relaxes intraocular smooth muscles. This further supports that cellular relaxation could be an important mechanism by which LAT-B decreases outflow resistance in the TM, since H-7, which decreases outflow resistance primarily by relaxing the TM, 26, 27 also relaxes the iris sphincter in vivo and ciliary muscle strips in vitro. 19 More interestingly, although 0.02% LAT-B appears to substantially, if not completely, inhibit the miotic response of the monkey eye to pilocarpine, it only inhibits the accommodative responsetothemuscarinicagonistbyupto25%.Phenylephrineinduced bilateral mydriasis may allow LAT-B's inhibition of the pilocarpine-induced miosis to be observed more easily but does not affect the conclusion since phenylephrine was administered bilaterally. The reason for the separation is not clear, but a pharmacokinetic explanation seems plausible. 19 Pilocarpine is a classical antiglaucoma medication that indirectly increases outflow facility by contracting the ciliary muscle. However, the induced miosis, which reduces vision especially in elderly patients with incipient cataract, 28 restricts its use. Although higher doses of pilocarpine may be more resistant to inhibition by LAT-B, the relative dissociation of miotic and accommodative responses to pilocarpine (as used in this study) after LAT-B administration provides a possibility that the combination of a low but still facility-effective topical dose of pilocarpine with a facilityeffective and cornea-safe topical dose of LAT-B may induce a facility increase greater than that induced by either drug alone, without damaging the cornea or constricting the pupil. Further studies are needed to prove this hypothesis.
Collectively, the fact that 0.005% and 0.01% topical LAT-B increase outflow facility and/or decrease IOP without adversely affecting the cornea suggests that a low dose of topical LAT-B may have potential as a safe and TM-selective antiglaucoma medication.
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